Korun Botai Bio-B subscribes to a structured deposit of CNY 0.25 billion from the Bank of Chengdu.

Korber Biotech-B (06990) announced that on July 9th and July 24th, 2024, the company respectively entered into Chengdu Bank Structured Deposit Agreement I and Chengdu Bank Structured Deposit Agreement II. Accordingly, the company agreed to subscribe to two structured deposits with a total amount of RMB 50 million yuan and RMB 0.2 billion yuan respectively. As of the date of this announcement, the total unpaid principal amount of structured deposits placed with Chengdu Bank is RMB 0.25 billion yuan.

新浪港股19:33 ET

Express News | Sichuan Kelun-Biotech Biopharmaceutical - to Subscribe for 2 Structured Deposits From Bank of Chengdu of RMB50 Mln and RMB200 Mln

ReutersJul 24 09:28 ET

[Brokerage Focus] GTJA initiates Corunbolti Bio (06990) with a "shareholding" rating, expecting core products to enter harvest period one after another and potential catalysts to be abundant.

Guowei Junan's research report states that Kelunbotai Biopharmaceutical (06990) has close cooperation with the global pharmaceutical giant Merck on multiple ADC pipelines. Among them, SKB264 has become a key asset of Merck in the field of cancer and has sequentially launched 10 key clinical trials. The clinical layout of SKB264 at home and abroad focuses on two core areas: breast cancer (including TNBC, HR+HER2-BC) and non-small cell lung cancer (including EGFR-TKI resistance and wild-type front-line treatment), as well as gastric cancer, urothelial cancer, endometrial cancer, etc. It is expected to become a new treatment for pan-cancer.

金吾財訊Jul 23 03:20 ET

CMB International: bullish on the rebound of Mainland China's pharmaceutical industry, with continued bullish policy implementation.

Zhaojin International continues to be bullish on Shenzhen Mindray Bio-Medical Electronics, United Imaging Medical, Innovent Bio (01801), Beigene (06160), Genscript Biotech (02273), Kelun Pharma (06990), and Anpac Bio-Medical Science (02367).

Zhitong FinanceJul 21 23:28 ET

Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.

It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.

Zhitong FinanceJul 18 08:31 ET

H.K. stocks connection: KeLunBoTai biology (06990) rose by 3.74%. Its strong R&D capability in ADC is pointed out by the institutions, and it is expected to benefit from the support of innovative drugs policies.

Sinolink Securities stated that the share price of Kexingbio (06990) has risen by 3.74% to HKD 155.3 as of the time of publication, with a turnover of HKD 76.0615 million. The company is a leader in domestic TROP2ADC and has reached three cooperation agreements involving ADC assets respectively with Merck&Co., Inc. in 2022 and 2023. Other key products that Merck&Co., Inc. and the company are cooperating on, including SKB315 (MK-1200, CLDN18.2ADC) and SKB410 (MK-3120, NECTIN-4ADC), are also undergoing global clinical trials.

金吾財訊Jul 17 01:48 ET